Biomarker exploration and personalized therapeutic directions for IL-17 pathway antibodies

Why biomarkers are needed

The clinical response rate of IL-17 pathway antibodies is considerable in most indications, but some patients still have limited efficacy or develop secondary failure. Differences in inflammatory phenotypes, genetic backgrounds, and comorbid conditions among patients may lead to inconsistent responses to the same drug. The core value of biomarkers lies in predicting efficacy before treatment or assessing it early during treatment, thereby helping clinicians more precisely select IL-17 pathway antibodies or change treatment strategies.

Pharmacodynamic and immunological indicators

Studies have examined the relationship between serum levels of cytokines such as IL-17A, IL-17F, and IL-23 and treatment response, but the results are not yet fully consistent. Some studies report reductions in skin or joint inflammation indicators after 4 to 16 weeks of treatment, but baseline absolute cytokine levels may not accurately predict long-term efficacy. In addition, detection of drug trough concentrations and anti-drug antibodies is gradually being applied in clinical monitoring, explaining low response or drug tolerance phenomena from a pharmacokinetic perspective. In general, results should be interpreted according to the validation status of the specific kit, and a single indicator should not be used as the sole basis for decision-making.

Exploration at the tissue and genetic levels

Immune cell infiltration patterns and key gene expression profiles in skin and synovial tissue may provide deeper information. For example, high expression of IL-17 pathway-related genes in skin lesions was once considered to be associated with better short-term response, but difficulties in sample collection and insufficient standardization have constrained clinical adoption. Genetic studies involve loci such as HLA-Cw6 and IL23R, and their associations with IL-17 pathway antibody response differ across populations, suggesting the need for comprehensive analysis incorporating racial background and clinical phenotype.

Actionable clinical pathway

Based on existing evidence, a comprehensive assessment framework can be established that includes disease severity, prior treatment history, rapid skin clearance rate, and improvement in quality of life. The degree of response early in treatment (e.g., at weeks 12 to 16) is often used as a reference window for continuing or adjusting treatment. If there is still no significant improvement after adequate exposure, consideration may be given to whether there is an inflammatory pathway not predominantly driven by IL-17, or whether to switch to a biologic with a different mechanism of action. In the future, with the development of multi-omics technologies and the establishment of prospective cohorts, biomarker-driven individualized treatment with IL-17 pathway antibodies is expected to gradually move into practice.

Conclusion

Biomarker research is driving the transformation of IL-17 pathway antibodies from "homogeneous treatment" to "selection on demand," but substantial validation is still needed before routine clinical application. At the current stage, attention should be paid to the accumulation of multidimensional data while avoiding overinterpretation of single laboratory values. Progress in this field will further enhance the precision management of chronic inflammatory diseases and ultimately improve patients' long-term prognosis.